BioMarin and n-Lorem Foundation Collaborate on Treatment for Rare Genetic Disorder ReNU Syndrome
BioMarin Pharmaceutical (BMRN) has announced a collaboration with the n-Lorem Foundation to develop an antisense oligonucleotide therapy targeting ReNU syndrome, a rare neurodevelopmental genetic disorder. The condition is marked by moderate-to-severe developmental delays, intellectual disability, and low muscle tone. This partnership aims to advance research into potential treatments for this underdiagnosed disease. The collaboration highlights BioMarin's ongoing efforts in the field of rare diseases through innovative therapeutic approaches such as antisense oligonucleotides. The n-Lorem Foundation is dedicated to supporting research on genetic disorders, and its involvement underscores a shared commitment to addressing unmet medical needs for patients with ReNU syndrome. This development could position BioMarin at the forefront of therapies targeting rare neurological conditions, potentially expanding their portfolio in high-impact therapeutic areas.
Tickers: $BMRN
Topics: antisense therapy biotechnology genetic disorders rare diseases